Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27.
- Breakthrough Findings On NV-387
- Efficacy Across Multiple Models
- Potential Revolutionary Antiviral Agent
Breakthrough Findings On NV-387
NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal flat blood concentration profile for an extended duration upon oral administration in two different animal models. This rare but highly desirable extended flat time profile of NV-387 in the bloodstream enables a sustained antiviral effect over a prolonged period, allowing for infrequent dosing regimens.
Specifically, the blood concentration of NV-387 peaked within the first hour and remained nearly constant for eight hours or longer. Subsequently, the concentration declined to baseline at around twelve hours following the oral administration of the initial dose. This was consistently observed in studies involving rats and dogs.
Efficacy Across Multiple Models
Additionally, NanoViricides recently reported that when NV-387 was administered as a slow bolus intravenous infusion, it resulted in a relatively flat blood concentration plateau with a very slow decline over a 24-hour period in a cynomolgus monkey model. The company had previously demonstrated that orally administered NV-387 produced strong antiviral effects against several respiratory viruses.
In lethal infections with hCoV-NL63, RSV, and Influenza A/H3N2, orally administered NV-387 outperformed approved therapeutics where available. Notably, in a rat model of deadly lung infection with RSV A2, NV-387 allowed for the full recovery from RSV infection.
Potential Revolutionary Antiviral Agent
First-in-class, broad-spectrum antiviral medication NV-387, may revolutionize treatment for viruses including RSV, COVID-19, influenza, and maybe others. NNVC's claim is also supported by non-clinical pharmacokinetic studies of the medication when administered orally that NV-387's systemic circulation and direct antiviral actions are responsible for the strong antiviral effects shown in animal efficacy trials.
NanoViricides also highlighted that NV-387 may be among the first or one of the few nanomedicines effective upon oral administration, a notable advancement given that nanomedicines are typically restricted to injectable or topical delivery methods.
納米病毒殺手公司(NanoViricides, Inc.)股票(NYSE: NNVC)發佈了令人鼓舞的臨床試驗數據後,在美國股票圖表上顯示出看好的趨勢。截至最新的當前市場檢查,NNVC股票上漲7.92%至3.27美元。
- 關於NV-387的突破性發現
- 多個模型下的療效
- 潛在的革命性抗病毒藥物
關於NV-387的突破性發現
納米病毒殺手(NNVC)報告稱,其主要臨床階段的廣譜抗病毒藥物候選者NV-387,在兩種不同的動物模型中口服後呈現出理想的平穩血濃度曲線。NV-387在血液中的這種罕見但極爲理想的延長平穩時間曲線,可在較長時間內實現持續的抗病毒效果,從而允許不頻繁的給藥方案。
具體地,NV-387在首小時內濃度最高,口服後血液濃度一直保持穩定,持續八小時以上。隨後,在大鼠和狗的研究中一致地觀察到初始劑量口服後十二小時左右,濃度降至基線。
多個模型下的療效
此外,納米病毒殺手最近報告稱,在長尾猴模型中,緩慢推注NV-387導致相對平穩的血濃度平台,血濃度在24小時內緩慢下降。該公司此前已證明,口服NV-387對幾種呼吸道病毒具有強烈的抗病毒作用。
在Lethal Infections with HCoV-NL63、RSV和Influenza A/H3N2中,口服NV-387表現超過現有已批准的治療藥物。值得注意的是,在針對RSV A2的致命肺部感染的大鼠模型中,NV-387可以讓病情完全恢復。
潛在的革命性抗病毒藥物
首個廣譜抗病毒藥NV-387可能通過革新治療方法革新多種病毒的治療方法,包括RSV、COVID-19、流感等。NNVC的主張也得到了該藥物口服時的非臨床藥代動力學研究的支持。NV-387的系統循環和直接抗病毒作用是動物療效試驗中強烈的抗病毒效果的原因。
此外,納米病毒殺手還強調,NV-387可能是口服後有效的頭一批或少數納米醫學,這是一個值得注意的進步,因爲納米醫學通常限制在注射或局部給藥方法。